logo
Nurse wrongly suspended after patient claimed she was pregnant with his child wins huge payout

Nurse wrongly suspended after patient claimed she was pregnant with his child wins huge payout

News.com.au08-05-2025

A British nurse who was wrongly suspended for two years after a patient claimed she was pregnant with his child has won a huge payout.
Jessica Thorpe was investigated after the man, named only as Patient X, said the pair were involved in an 'inappropriate relationship'.
He was a patient on a secure facility for men with mental disorders who have come into contact with the criminal justice system, The Sun reports.
The patient claimed Thorpe was 'pregnant with his child', leading health authorities to suspended her three days later.
She eventually was told she could continue her work with the NHS in the northern England region of Cumbria, Northumberland, Tyne and Wear in October 2022, but the outraged nurse resigned a month later in protest.
Thorpe has now been awarded £24,118 (about $50,000 Australian Dollars) after she won a claim for unfair dismissal, breach of contract and unlawful deduction of wages.
A judge previously said he would not address or make factual findings on Patient X's allegations as he ruled in the nurse's favour.
The court heard Thorpe began working for the trust in early 2020 but was suspended in April that year when the claim was made.
A hearing eventually took place in July 2021 – more than a year after the allegations arose – by which time Patient X had passed away.
The panel heard how there may have been a 'blurring of boundaries' due to the patient 'responding well' to the nurse.
The allegation of inappropriate behaviour was not upheld due to a lack of 'conclusive evidence'.
Despite the ruling, Thorpe was told she would not be returning until a police probe into Patient X's death was completed.
Judge Simon Loy said there was an 'enormous period' where Thorpe was suspended but said the 'real issue' arose from the trust's decision not to allow her back to work after the disciplinary hearing.
During her suspension, the nurse launched a food influencer account on Instagram called 'Slice of Jess', which amassed more than 50,000 followers.
She also began making YouTube videos and started earning money from her content.
Tax returns shown to the tribunal revealed her income from Google soared from £4,211 ($8700) in 2021 to £19,222 ($39,700) in 2023.
The trust tried to argue that Thorpe only resigned from her role as she wanted to 'pursue her career as a social media influencer'.
But Thorpe said she only started posting content as a 'hobby' during her suspension.
She also told the trust when resigned that she was doing so because the trust failed to address any 'gossip' about the 'alleged relationship' from colleagues.
Judge Loy accepted her desire to pursue a career as a social media influencer was 'influential' on her decision to leave.
He said he had 'considerable sympathy' for their position as in 'other contexts', the breach could be considered to have been 'remedied'.
But he added: 'However, the tribunal must apply the applicable legal principles.
'If the duration of [Miss Thorpe's] suspension gave her an opportunity to explore the potential for social media activities to generate income then so be it.'
Thorpe has since taken to social media to respond to the outcome, writing: 'My shoulders have dropped, my jaw has unclenched. It's finally over after 5 years of hell.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

National review launched into IVF accreditation following second Monash embryo mix-up
National review launched into IVF accreditation following second Monash embryo mix-up

ABC News

time6 hours ago

  • ABC News

National review launched into IVF accreditation following second Monash embryo mix-up

All Australian states and territories will undertake a review into the implementation of an independent verification body for fertility providers. Victorian Health Minister Mary-Anne Thomas said health ministers met on Friday and agreed to a three-month rapid-review into the sector, which is currently accredited by the Reproductive Technology Accreditation Committee. "It simply doesn't pass the pub test that the people that provide the service are also the ones that determine who provides the service," she said. The announcement comes after two separate embryo mix-ups by Melbourne-based provider Monash IVF were revealed in a matter of months. Ms Thomas said her preference was for the immediate implementation of a regulator, however this was rejected by Queensland Health Minister Tim Nicholls. Ministerial meetings by health ministers operate on a consensus, meaning all ministers must agree to make any changes nationally. "I think it's concerning that there may well be further errors that we don't know about," she said. "And that is because the body that currently accredits fertility care providers is made up of fertility care providers. that's why I find Queensland's position so perplexing." This week, Monash IVF announced to the ASX it would conduct an internal investigation into an embryo mix-up at its Clayton laboratory in Melbourne's south-east earlier this month. That announcement, which came months after the revelation another patient of Monash IVF in Brisbane gave birth to a stranger's baby in 2023, sparked calls for greater regulation of the field. Monash IVF chief executive officer Michael Knaap also resigned earlier this week. On Friday afternoon Mr Butler said he was "really worried about public confidence" in the sector, which he said needed greater transparency and independent accreditation for fertility service providers. "We know that in the last full year there were dozens of breaches of the code of conduct but I don't know, as the federal health minister, what they were," he said. "They are not reported, they are not disclosed." He said health officials across the country would provide advice on whether Australia should move towards national regulations. "There are essentially eight systems of regulation across the country," he said. "It would take a bit of time to move to more national regulation."

Scott Power: ASX stocks fall as investors hear mixed news from Cochlear
Scott Power: ASX stocks fall as investors hear mixed news from Cochlear

News.com.au

time7 hours ago

  • News.com.au

Scott Power: ASX stocks fall as investors hear mixed news from Cochlear

ASX heath sector falls 1.1% over past five days, while broader markets flat as Middle East tensions flare Cochlear downgrades full-year profit expectations but launches a world first Monash IVF head Michael Knaap resigns after another embryo mix-up Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his 'Powerplay' stock pick. It was a big week of news for the ASX healthcare sector with the bourse's fourth largest biotech Cochlear (ASX:COH) downgrading its FY25 net earnings ~4% to $390-400 million, compared with prior guidance in February of $410-430m, on "slower-than-expected sales growth over the last few months". Morgans' healthcare analyst Derek Jellinek wrote in a note to clients consensus for the hearing tech company sat at $411m with Morgans at $412m. While Cochlear continues to expect implant units to grow ~10% in FY25, growth will be weighted to emerging markets as developed market growth has been impacted by slower-than expected market growth and a "small loss" of market share in a few countries. Cochlear now expects services revenue to decline by low double-digits compared to prior expectations for a single-digit decline. "COH believes ongoing work to identify and connect with recipients who could benefit from the latest sound processing technology, combined with the introduction of the new off-the-ear Nucleus Kanso 3 sound processor, which is expected to launch in EU and APAC mid-Jun-25, should lift services revenue in FY26," Jellinek wrote. Following a disappointing H1 FY25 result, Morgans highlighted risks in the services segment (around 25% of sales), driven by slower-than-expected uptake of the Nucleus 8 sound processor, which was launched in FY23, and cost-of-living pressures delaying device replacements. But in some positive news, Cochlear also announced the launch of Nucleus Nexa, the world's first and only smart cochlear implant system, saying it was the "outcome of a 20 year investment in R&D". "A couple of key features include upgraded firmwear, the smallest sound processor and internal memory so that has actually countered the profit downgrade they've announced," Power said. Morgans has a hold rating on Cochlear with a 12-month target price of $285.55. Monash chief quits following another embryo mixup A new acting CEO has been appointed to steer the troubled Monash IVF Group (ASX:MVF), which fell ~27% on Tuesday after reporting another embryo implant bungle. Monash announced on Thursday CEO and managing director Michael Knaap had resigned with CFO and company secretary Malik Jainudeen appointed acting CEO. In the latest incident a patient's own embryo was mistakenly transferred to them, rather than their partner's embryo as specified in the treatment plan at Monash's Clayton laboratory in Melbourne on June 5. Monash said it was conducting an internal investigation to determine the cause of the incident and notified the relevant assisted reproductive technology (ART) regulators, the Victorian health regulator and its insurers. It comes after Monash revealed in April a woman had given birth to a baby that was not hers after receiving the wrong embryo at a Brisbane clinic. An independent review by Fiona McLeod AO SC regarding that incident is currently ongoing and has been extended, with the findings yet to be disclosed. Monash confirmed that its updated profit guidance, issued on May 20, remains unchanged, projecting an underlying NPAT of $27.5 million. Morgans maintains a speculative buy on Monash with a 12-month target price of $1. Israel strikes on Iran add to market uncertainty At 1.45pm on Friday the S&P/ASX 200 Health Care index was down 1.1% for the past five days, while the benchmark ASX 200 was flat for the same period. Markets took a tumble on Friday after reports of Israel strikes against Iran's nuclear sites with the Middle East bracing for retaliation. Power said the escalating conflict adds further complexity to global equity markets still very much being driven by macroeconomic factors and geopolitical tensions. "Markets are still very much broader macro driven including with US President Donald Trump's trade and regulatory policies," Power said. "Investors will now be closely monitoring the escalating tensions in the Middle East." Power's Powerplay: EBR completes raise, starts US rollout EBR Systems (ASX:EBR) is Power's stock of the week after announcing completion of a share purchase plan (SPP) and that the first US commercial patients have been implanted with its WiSE CRT System, the world's only wireless solution for pacing the left side of the heart. The procedures took place at St David's Medical Centre and the Cleveland Clinic, two of several leading US institutions participating in this pilot release of the WiSE CRT System, which was approved by the FDA in April. EBR said the cases represented two of the main indications for WiSE. "Clearly, the first commercial patients implanted with WiSE is a key milestone, as EBR has officially transitioned from a pure R&D focus to a commercial entity," Jellinek wrote in a note to clients. He said importantly, the implants were done in advance of reimbursement and the limited market release of WiSE, which remained on track for October, showcasing the unmet medical need in the initial US$3.6m total addressable market and belief in use of the device. "As this device is a novel treatment option requiring physician education, we view the LMR, targeting key heart failure centres in the US, as an appropriate strategic way to build familiarity and experience, prior to full market release," he wrote. "We see sales surpassing US$80m into CY29. "While certainly not a 'hockey stick', we believe it is a methodical, stage-gated rollout to build strong physician support and closely monitor clinical outcomes, helping to pique interest from any would-be suitor." The company also announced today it had finished its SPP raising $xxm and adding to a fully underwritten Institutional Placement raising $55.9m completed in May. Proceeds from the capital raise will be used to advance its US commercialisation strategy for WiSE. Morgans has a buy rating and 12-month target price of $2.86. Two positive studies for Avita Wounds management company Avita Medical (ASX:AVH) has announced the first clinical publication of its Cohealyx product, which is a collagen-based dermal matrix, in the Journal of Surgery. The publication includes two positive case reports on patients with complex hand wounds treated with Cohealyx. In both instances, the patients sustained full-thickness burns following syncopal episode (temporary loss of consciousness due to a drop in blood flow to the brain). The study showed significant acceleration of wound bed vascularisation and autograft readiness, achieving readiness within five to 10 days compared to the typical two to four weeks. "Clearly, a small sample size and this publication represents the first clinical validation of AVH's preclinical findings but it's a strong start and likely the first of many case-studies to come," Morgans' healthcare analyst Iain Wilkie wrote in a note to clients Avita also announced a new study of its flagship spray-on skin treatment Recell showed it reduced hospital stays by 36% compared to traditional skin grafts. Presented at the British Burn Association's annual meeting, the US-based study analysed outcomes for more than 6,300 patients treated with Recell between 2019 and 2024. All patients had burns covering less than 30% of their total body surface area. The findings showed Recell patients spent on average 6.2 fewer days in hospital, delivering an estimated $300m in healthcare savings over the five-year period. Wilkie wrote that the share price had continued to remain weak following series of missed guidance expectations and dwindling cash reserves. "The point with Avita is they've expanded their product range to treat more of the wound complex and what the market is concerned about is do they need to raise additional funds," Power said. "They've told the market they can see a pathway through to profitability or breakeven by the fourth quarter of this calendar year so as each quarter rolls on we will get more confident that they're able to achieve that." Morgans has a speculative buy rating on Avita and 12-month target price of $3.76. Imricor gets CE Mark for NorthStar Mapping System Imricor Medical Systems (ASX:IMR) has received CE mark (European) certification for its NorthStar Mapping system under the new, more stringent European Union Medical Device Regulations (MDR). NorthStar has been approved as a Class IIa medical device with the certification received ahead of schedule. Imricor is advancing technology for real-time interventional cardiac magnetic resonance (iCMR) ablations, enabling cardiac ablation procedures to be guided by live MRI imaging instead of traditional x-ray fluoroscopy. NorthStar is a key component of its product offering. The certifications follows on from recent European approvals received for its Advantage-MR EP Recorder/Stimulator (Advantage-MR), and its second generation Vision-MR Ablation Catheter. "Imricor will now phase out first generation products approved under the old EU regulations, replacing them with new MDR approved devices," Power said. "We expect sales momentum to steadily build over coming quarters." Power said next catalysts to watch for include additional sales orders in Europe and Middle East and US FDA approval for NorthStar. Imricor is also undertaking its Vision-MR Ablation of Atrial Flutter (VISABL-AFL) pivotal clinical trial to support FDA approval of its products, which it hopes to achieve in 2025. In Europe, where Imricor has already received regulatory approval for atrial flutter, the company has started a pivotal VISABL-VT clinical trial for its second indication, ventricular tachycardia (VT). Morgans has a speculative buy on Monash and 12-month $2.28 target price. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article.

ABC Radio Sydney presenter James Valentine announces omentum cancer diagnosis
ABC Radio Sydney presenter James Valentine announces omentum cancer diagnosis

ABC News

time8 hours ago

  • ABC News

ABC Radio Sydney presenter James Valentine announces omentum cancer diagnosis

I'd really hoped I'd never have to do this again. I've now twice gone on the radio on 702 ABC Sydney, and published articles online, revealing details of my disease. In March 2024, I announced that I had oesophageal cancer, and I was heading off for major surgery and it might be a while before I'd be back. In September 2024, I came back on air, and let everyone know, that I'd had a more minor procedure, removed the tumour in my oesophagus and would then be monitored for any future outbreaks. Well, here in June 2025, I'm telling you the monitoring works very well. My current scans, and a biopsy have confirmed that I have tumours in my omentum. Yes, omentum, I'd never heard of it either. It's described usually as a fatty veil, which extends from the stomach over your intestine. Quite what it does, not sure; partly packaging, partly helping to protect the intestine, possibly some role in dealing with infection. Whatever it's meant to do it is currently largely squeezing my bowel and causing constriction and constipation and general discomfort in that part of the world. Oh, it's been a fun few weeks, my friends. I am now way too familiar with the 'digestive' aisle of my local chemist. So I've been off the last couple of weeks, getting tests, and figuring out what's to be done. As of next week, I will be beginning chemotherapy and immunotherapy. A big blast of 21st century science, that hopefully, will scour it all out and leave me in a position to heal and recover. Immunotherapy is the great hope of everyone these days. I'm eligible, as in it's considered that it's very likely to be effective in my case. I won't be able to keep working so I'll be off air now for at least three months. Side effects of the treatment range from mildly irritating to horrendous, so I think I'll just deal with them. Best I focus on this one thing, and give the medicine and the process its best chance. I've been back playing saxophone and doing some gigs and some live theatre shows as well which, from my point of view on the stage, have been wonderful! So they too will be put on hold for a while until this cancer has abated. Back when this cancer was just a tumour in short pants in my oesophagus I was faced with a choice between the full removal of my oesophagus or the removal of only the tumour, leaving my oesophagus intact. I accepted then that I was making the decision on what I would do. The difficulty with the decision was that both doctors were right; the full surgery was more common and the accepted protocol for my condition, but the lesser procedure was possible. The way I often expressed it then and since, has been to say that I chose a different set of risks. To remove the oesophagus fully was likely to leave me with a long recovery and a potential set of morbidities and difficulties in living that would be challenging. To remove the tumour was to accept that I'd be initially OK, but cancer could return. In fact, in both procedures there was always the likelihood of future cancer. The future's arrived. There may be debate as to whether the full removal might have prevented this, but given that the initial tumour may have been there for a while, undetected and asymptomatic, there's every chance that cancer cells have been out in my body for some time, looking for a place to call home, and the full surgery would not have prevented their spread. I'm not that concerned about that, the how, the why, the might have been. I find cancer, like any other major insult to my being, has a way of bringing me very firmly into the present. What's happening to me, what can I do to fix this, what do I need to do right now this day, this hour, this minute? That's me for the next few months. Treatment, deal with the treatment, rest, build strength for next treatment. In between, be with the people I love. I'm already missing you, I'm already wanting to get back on air. All is not right unless I'm on the radio in the afternoon and there's Rant, and Petty Crimes being solved and couples sharing on This Is What I Live With and all the other glorious, revealing, hilarious and shambolic conversations we share every day. I don't pray, but if you do, please go hard. I can feel your good wishes, love and support and I thank you deeply for it. When I know anything about what's happening, I'll let you know but right now I'm off to the land of the sick. When I get back, you'll hear from me.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store